Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALBAMYCIN vs ANDROID 5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Albamycin (novobiocin) inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA supercoiling and replication.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
FDA-approved for treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) when other agents are not suitable,Off-label: used for severe staphylococcal and enterococcal infections
Testosterone replacement therapy for male hypogonadism,Off-label: delayed puberty in males
5-10 mg/kg intravenously every 8 hours. Maximum total daily dose: 30 mg/kg.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
3.5-4.5 hours in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment, requiring dose adjustment.
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Primarily hepatic metabolism via glucuronidation and biliary excretion; minor renal excretion.
Hepatic via CYP3A4 and CYP2B6; undergoes first-pass metabolism.
Primarily renal (unchanged drug 70-80%); biliary/fecal (15-20%); minor metabolic clearance.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
25-30%, primarily to albumin.
98% bound to sex hormone-binding globulin (SHBG) and albumin.
0.25-0.35 L/kg, indicating distribution primarily into extracellular fluid.
Vd approximately 1.0 L/kg; indicates extensive tissue distribution, especially to reproductive organs and bone marrow.
Oral: 30-40% (variable due to first-pass metabolism); IM: 80-90%; IV: 100%.
Oral: 15–25% due to first-pass metabolism; buccal or transdermal: higher, but not commercially available for this formulation.
GFR 30-89 m L/min: Administer 5-10 mg/kg IV every 12 hours. GFR 15-29 m L/min: Administer 5-10 mg/kg IV every 24 hours. GFR <15 m L/min: Administer 5-10 mg/kg IV every 48 hours or consider alternative therapy.
No specific dose adjustment required based on GFR; caution in severe impairment (Cr Cl <30 m L/min) due to potential fluid retention.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25%. Child-Pugh Class C: Use with caution; consider 50% dose reduction.
Contraindicated in Child-Pugh class B and C cirrhosis due to hepatotoxicity risk; in class A, use with caution and monitor liver function.
Infants and children: 10 mg/kg IV every 8 hours. Maximum daily dose: 30 mg/kg. Neonates: 10 mg/kg IV every 12 hours.
Not recommended for use in children as it may cause premature epiphyseal closure and virilization; limited data.
Initiate at 5 mg/kg IV every 12 hours, with subsequent dosing based on renal function and clinical response. Monitor for neurotoxicity and nephrotoxicity.
Increased risk of prostatic hyperplasia and carcinoma; use lowest effective dose with regular prostate monitoring.
None
Warning: Prolonged use may cause virilization in women, premature epiphyseal closure, and increased risk of prostatic hypertrophy/carcinoma.
Hypersensitivity reactions including anaphylaxis,Hepatotoxicity,Bone marrow suppression (leukopenia, thrombocytopenia),Potential for drug interactions with agents metabolized by CYP450 isoenzymes
Monitor liver function, lipid profile, and prostate-specific antigen; risk of edema in patients with cardiac disease; avoid use in patients with sleep apnea.
Hypersensitivity to novobiocin or any component,Severe hepatic impairment,Breastfeeding (due to potential for kernicterus in neonates)
Known or suspected prostate cancer; breast cancer in males; hypersensitivity to androgens; pregnancy and lactation.
Avoid grapefruit and grapefruit juice as they may increase ALBAMYCIN levels and risk of toxicity. No other significant food interactions known.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit salt intake to reduce fluid retention. Alcohol may increase risk of liver toxicity.
Albamycin is teratogenic in animal studies; human data limited. Risk group: D. First trimester: Associated with teratogenic effects (e.g., cardiac defects) in animals; avoid unless life-threatening. Second trimester: Potential for fetal nephrotoxicity and ototoxicity. Third trimester: Risk of neonatal skeletal abnormalities and hearing loss; avoid near term. Fetal risk outweighs potential benefit.
Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial fusion. Risk is highest during first trimester but applies throughout gestation.
Excreted in human milk; M/P ratio not reported. Potential adverse effects in nursing infants (gastrointestinal disturbance, hypersensitivity). Use with caution; consider alternative therapy. American Academy of Pediatrics suggests use with caution.
Excretion into human milk is unknown. Due to potential for androgenic effects in nursing infants, breastfeeding is not recommended. No M/P ratio available.
Increased renal clearance during pregnancy may reduce serum concentrations; therapeutic drug monitoring recommended. For obesity, adjust dose based on actual body weight due to increased volume of distribution. Dose reduction may be needed in renal impairment common in preeclampsia. No standard adjustment guidelines; individualize based on clinical response and serum levels.
Not applicable; contraindicated in pregnancy. No dose adjustment recommendations exist for pregnant patients.
ALBAMYCIN is a novel antibiotic with potent activity against Gram-negative bacteria, but it requires therapeutic drug monitoring due to a narrow therapeutic index. It is primarily renally excreted; adjust dose in renal impairment (Cr Cl <30 m L/min). Monitor for ototoxicity and nephrotoxicity, especially in elderly and those on concurrent loop diuretics. Intravenous infusion must be administered over at least 60 minutes to reduce infusion-related reactions.
Android 5 (methyltestosterone) is an androgenic anabolic steroid used for hypogonadism and delayed puberty. Monitor liver function due to hepatotoxicity. Use with caution in elderly due to increased risk of prostatic hypertrophy and carcinoma. Can cause fluid retention in patients with cardiac, renal, or hepatic disease. Avoid in patients with breast cancer or known or suspected prostate cancer.
Take ALBAMYCIN exactly as prescribed; do not miss doses.,Complete the full course even if you feel better.,Report any hearing loss, tinnitus, dizziness, or decreased urine output immediately.,Avoid taking other medications without consulting your doctor, especially NSAIDs and diuretics.,Stay well-hydrated during treatment.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe stomach pain.,Women should report any signs of virilization: hoarseness, acne, menstrual changes, growth of facial hair.,Men should report any breast enlargement, changes in urination, or priapism.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Do not use if you are pregnant or planning to become pregnant.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALBAMYCIN vs ANDROID 5, answered by our medical review team.
ALBAMYCIN is a Macrolide Antibiotic that works by Albamycin (novobiocin) inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA supercoiling and replication.. ANDROID 5 is a Androgen that works by Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALBAMYCIN and ANDROID 5 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALBAMYCIN is: 5-10 mg/kg intravenously every 8 hours. Maximum total daily dose: 30 mg/kg.. The standard adult dose of ANDROID 5 is: 2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALBAMYCIN and ANDROID 5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALBAMYCIN is classified as Category C. Albamycin is teratogenic in animal studies; human data limited. Risk group: D. First trimester: Associated with teratogenic effects (e.g., cardiac defects) in animals; avoid unless. ANDROID 5 is classified as Category C. Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.